Gilead Sciences names its new health leader for Asia markets

Dustin Haines has 20 years leadership in pharmaceuticals.

To improve public health and community in five Asian markets, Gilead Sciences, a biopharmaceutical firm, appointed pharmaceutical veteran Dustin Haines as its general manager and vice president for Asia 5 starting 6 June 2022.

Haines, who served corporate leadership in pharmaceuticals for 20 years, will be at the helm of driving the business development of HIV and viral hepatitis including hepatitis B, C, and D, as well as Gilead’s commitment to boosting public health and community impact in Hong Kong, Singapore, South Korea, Taiwan, and Malaysia.  

Prior to his appointment, Haines served as the chief commercial officer of Next Science, a medical technology firm. 

For over 10 years, he worked with ViiV Healthcare and GSK, last serving as president and general manager for Japan at ViiV Healthcare.